Washington Post, March 16, 2024: New study results showing that the ALS drug Relyvrio does not work raises important questions about FDA’s decision to be flexible about approval even when the scientific evidence is lacking. We explain that the pendulum has swung too far and each questionable approval results in more pressure on FDA to make more questionable approvals.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Why journalists should scrutinize the FDA’s accelerated drug approval process
Healthjournalism.org, March 7, 2024 article by Association of Health Care Journalists explains the problems with the FDA accelerated approval process and gives advice on how to cover the evidence accurately. NCHR’s Diana Zuckerman explains that when FDA rescinded approval of the cancer drug Pepaxto, it was an easy call because the company took it off the market 2 years ago because of the higher death rate in a clinical trial.
Read More »Accelerated Approval Withdrawal Offers Hints On New FDA Approach
Inside Health Policy, March 4, 2024: NCHR was interviewed regarding the FDA rescinding accelerated approval for Pepaxto for multiple myeloma. We explain that the FDA’s new “’streamlined’ path to reverse approval decisions still takes years even after there is proof that patients taking the drug are more likely to die.
Read More »A Closer Look at Aduhelm, CTE, and the Super Bowl: Insights from STAT Readers
February 11, 2024: NCHR was quoted in Medriva regarding our commentary on the evidence FDA should require to prove safety and efficacy of treatments used by older patients, which was also discussed in Letters to the Editor and comments to STAT.
Read More »Deep flaws in FDA oversight of medical devices — and patient harm — exposed in lawsuits and records
CBS News, December 20, 2023: CBS News article dives into the lack of FDA oversight within the medical device industry. Increased patient harm is exposed in lawsuits and records.
Read More »